Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
| Authors | Kenjiro Aogi, Kenichi Watanabe, Masahiro Kitada, Takafumi Sangai, Shoichiro Ohtani, Tomoyuki Aruga, Hidetoshi Kawagichi, Tomomi Fujisawa, Shigeto Maeda, Takashi Morimoto, Nobuaki Sato, Shintaro Takao, Satoshi Morita, Norikazu Masuda, Masakazu Toi, Shinji Ohno |
| Journal | International journal of clinical oncology
(Int J Clin Oncol)
Vol. 26
Issue 7
Pg. 1237
(Jul 2021)
ISSN: 1437-7772 [Electronic] Japan |
| PMID | 34043103
(Publication Type: Published Erratum)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|
